Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Salt Lake City, Utah--(Newsfile Corp. - June 27, 2022) -  Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") received approval to initiate a first-in-human clinical trial for KIO-301, which is intended to restore lost vision in patients with Retinitis Pigmentosa, a rare, inherited genetic eye disease that causes severe loss of functional vision due to degeneration of the retinal photoreceptors (rods and cones). The ABACUS study is a Phase 1b open label, single ascending...

Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa

Allena Pharmaceuticals

GSX Techedu Inc.

Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on June 9th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 9th

Salt Lake City, Utah--(Newsfile Corp. - May 31, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced that on May 25, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q for the fiscal...

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Results support planned Phase 2 Trial to treat the Ocular Presentation of Rheumatoid Arthritis (OPRA)Salt Lake City, Utah--(Newsfile Corp. - April 25, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that the full results of the KIO-101 Phase 1b clinical trial are being presented at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting on April 25, 2022. The results of the vehicle-controlled, randomized clinical trial in patients with ocular surface inflammation demonstrated safety and tolerability of KIO-101 as well as statistically significant...

Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022

Salt Lake City, Utah--(Newsfile Corp. - April 15, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today reported its financial results for the quarter and year ended December 31, 2021 and provided an update on recent corporate and operational activities. "We are making significant progress advancing our pipeline of treatments for ocular disease," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "KIO-301 was recently granted orphan drug designation...

Kiora Pharmaceuticals Reports 2021 Results and Provides Business Update

- To Participate in Ophthalmology Roundtable March 28, 10:00-11:00 AM ET -- To Provide On-Demand Corporate Presentation -Salt Lake City, Utah--(Newsfile Corp. - March 21, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") has been invited to present at Maxim's 2022 Virtual Growth Conference March 28th - 30th. Company President and CEO, Brian M. Strem, Ph.D., will participate in a live ophthalmology roundtable discussion as well as provide an on-demand investor presentation....

Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th

The FDA has granted Orphan Drug designation to Kiora Pharmaceuticals Inc's (NASDAQ: KPRX) KIO-301 for Retinitis Pigmentosa. Retinitis Pigmentosa is an inherited genetic eye disease that can lead to severe vision loss due to rods and cones degeneration.

Kiora Pharma Snags Orphan Drug Tag For Inherited Genetic Eye Disease Candidate

Salt Lake City, Utah--(Newsfile Corp. - March 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational treatment of Retinitis Pigmentosa, KIO-301. Retinitis Pigmentosa is a rare, inherited genetic eye disease that can lead to severe loss of vision due to degeneration of rods and cones. Kiora expects to initiate clinical trials of KIO-301 in Q3 2022....

Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)

Bone Biologics Corp

Humanigen

Ra Medical Systems Inc

Biotech penny stocks to watch right now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Biotech Stocks To Watch Right Now

CooTek (Cayman) Inc - ADR

Guardion Health Sciences Inc

Northern Dynasty Minerals

Hot penny stocks to buy for under $1. Are they worth it in March 2022?

Hot Penny Stocks To Buy For Under $1 In March 2022

Salt Lake City, Utah--(Newsfile Corp. - February 8, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that Brian M. Strem, Ph.D, President and CEO of Kiora, will present a Company overview at the BIO CEO & Investor Conference on February 15th at 10:30AM Eastern. The conference will be held at the Marriott Marquis in New York City from February 14th until February 17th.Kiora's presentation will be available for download from...

Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference

Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman, Stephen From, has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately. "I am pleased to welcome Erin Parsons to our Board of Directors," said Brian M. Strem,...

Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board

Salt Lake City, Utah--(Newsfile Corp. - January 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian Strem, Ph.D., President and Chief Executive Officer, will provide an outlook for the business and its pipeline of treatments for ophthalmic diseases. The corporate presentation will be available on-demand and accessible from the Company's Investor Relations website starting Monday January 10, 2022 at 7:00 am Eastern...

Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference

The stock price of Kiora Pharmaceuticals Inc (NASDAQ: KPRX) increased by over 35% during intraday trading today. This is why it happened.

Kiora Pharmaceuticals Stock (KPRX): Why The Price Surged Today

Aridis Pharmaceuticals

Reliance Global Group

These penny stocks climbed during premarket trading today, here's why The post 3 Penny Stocks That Exploded in Premarket Trading Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Exploded in Premarket Trading Today

Salt Lake City, Utah--(Newsfile Corp. - December 15, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced the appointment of David Hollander, MD, MBA, to its Board of Directors. Dr. Hollander, who currently serves as the Chief Research and Development Officer of Aerie Pharmaceuticals, Inc. ("Aerie"), brings extensive ophthalmic industry expertise and insight to the Company's board. "Kiora has a compelling development pipeline, including KIO-301, a clinical-ready small molecule with the...

Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors

Salt Lake City, Utah--(Newsfile Corp. - December 14, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a key driver of dry eye disease. The results demonstrated favorable safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival hyperemia, a key inclusion criterion for...

Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities.

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Company's aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. The Company's newly revamped clinical development strategy is available in the Investors section of the Company's new website at www.kiorapharma.com.

EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy

News for Kiora Pharmaceuticals Stock (KPRX)